echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hiscoperindopril and indapamide tablets enter administrative approval and will win the first imitation of compound antihypertensive drugs

    Hiscoperindopril and indapamide tablets enter administrative approval and will win the first imitation of compound antihypertensive drugs

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Haisco has entered the administrative approval stage with the imitation of perindopril indapamide tablets reported for production in Category 4 and is expected to win the first imitation


    Perindopril and indapamide is a compound antihypertensive drug developed by French Servier.


    According to data from Meinenet, in 2020, the total sales of perindopril and indapamide in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 3 100 million yuan


    At the physical pharmacy terminals in Chinese cities, the sales of perindopril and indapamide have been rising steadily, from 34.


    Sales of perindopril and indapamide in physical pharmacies in cities in China (unit: ten thousand yuan)

    Source: Mi Nei.


    At present, only Servier has been approved for production of perindopril indapamide tablets in the domestic market, and Menova Tiankang and Haisco have submitted applications for perindopril indapamide tablets in imitation 4 categories


    Data source: Mi Neiwang database, NMPA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.